News | April 22, 2024
Evotech and Variant Bio partner to develop fibrosis treatment
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Sonoma will manufacture Ocudox by Avenova with packaging similar to NovaBay’s Avenova products
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
This DSIR recognition for company's in-house R&D Unit make it eligible for receiving funds for R&D purpose from various government departments and agencies
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
Subscribe To Our Newsletter & Stay Updated
